Venetoclax in lymphoid malignancies: new insights, more to learn
Author(s)
Thijssen, R; Roberts, AW;
Details
Publication Year 2019-10-14, Volume 36, Issue #4, Page 341-343
Journal Title
Cancer Cell
Publication Type
Journal Article
Abstract
In this issue of Cancer Cell, Guieza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.
Publisher
Cell Press
WEHI Research Division(s)
Blood Cells And Blood Cancer
PubMed ID
31614111
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2019-10-28 12:05:04
Last Modified: 2019-10-30 09:42:58
An error has occurred. This application may no longer respond until reloaded. Reload 🗙